SANOFI US SERVICES INC. for SANOFI US SERVICES INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 17, 2008 | $1,240,000 | Replaced |
| 3rd Quarter - Amendment | Dec 18, 2008 | $1,270,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
issues related to the issuance of compulsory licenses of innovative pharmaceuticals
Foreign entity interest: The protection of intellectual property rights n the US and other countries helps encourage ongoing research and development of innovative pharmaceutical and biotechnology treatments and advancs the quality of healthcare for people. To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN TAYLOR | — |
Taxation/Internal Revenue Code TAX
provisions related to the R&D tax credit in S2209 "Research Credit Improvement Act of 2007"; HR1424 "Emergency Economic Stabilization Act of 2009"; and S41 " Research Competitiveness Act of 2007"
Foreign entity interest: to the degree that such policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN TAYLOR | — |
Medicare/Medicaid MMM
Issues related to the Medicaid program
Foreign entity interest: to the degree that such policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
Health Issues HCR
Cancer awareness, including women's cancer program; issues related to Deep Vein Thrombosis (DVT) awareness and quality of care; issues related to diabetes care in the federal healthcare programs; and issues related to men's health
Foreign entity interest: to the degree that such policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| MARK COIN | — |
| RICHARD M HODGE | — |
| SAIRA SULTAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.